Associated Genetic Biomarkers
TYRO3 is altered in 0.04% of all cancers with lung adenocarcinoma, breast invasive ductal carcinoma, colon adenocarcinoma, oligodendroglioma, and ovarian serous adenocarcinoma having the greatest prevalence of alterations .
The most common alterations in TYRO3 are TYRO3 Mutation (2.37%), TYRO3 K318M (0.30%), TYRO3 P21R (0.30%), TYRO3 R452* (0.30%), and TYRO3 R678W (0.30%) .
TYRO3 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains TYRO3 status as an inclusion criterion, 1 is phase 2 (1 open).
Trials with TYRO3 status in the inclusion eligibility criteria most commonly target malignant solid tumor .
The most frequent alterations to serve as inclusion eligibility criteria are TYRO3 Amplification and TYRO3 Mutation .
Cabozantinib is the most frequent therapy in trials with TYRO3 as an inclusion criteria .
Significance of TYRO3 in Diseases
Malignant Solid Tumor +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.